CBIS - Cannabis Science, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Cannabis Science, Inc.

19800 MacArthur Boulevard
Suite 300
Irvine, CA 92612
United States
888-263-0832
http://www.cannabisscience.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Raymond C. DabneyCo-Founder, Chairman, CEO & Pres225kN/A1965
Mr. Benjamin C. K. TamCFO, Sec. & DirectorN/AN/A1952
Mr. Robert James KaneCOO & Director15kN/A1976
Mr. Mario LapPres of European Operations & DirectorN/AN/A1952
Mr. Alfredo Dupetit-BernardiCEO & Pres of Cannabis Science GmbH18.32kN/A1962
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid-based pharmaceutical products primarily in the United States. The company is developing medicines for autism, blood pressure, cancer, cancer side effects, and other illnesses, as well as for general health maintenance. Its drugs under development include CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions. In addition, the company offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, benefits of medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. Further, it operates an industrial hemp research and development project. It has collaboration with IGXBio, Inc. to develop GenePro, a DNA-based immunotherapeutic drug; and a research collaboration agreement with Dana-Farber Cancer Institute, Inc. to develop and investigate the use of cannabinoids to cure various cancers, as well as with Stellenbosch University to treat chronic pelvic pain associated with pelvic inflammatory disease in women, chronic prostatitis in men, and other chronic pain associated with other indications. Cannabis Science, Inc. also has a research collaboration agreement with Dana-Farber Cancer Institute, Inc. to investigate the use of extract from the Justicia plant to treat blood disorders. The company was formerly known as Gulf Onshore, Inc. and changed its name to Cannabis Science, Inc. in April 2009. The company was incorporated in 1996 and is based in Irvine, California. Cannabis Science, Inc. is a subsidiary of Weedmaps Media, Inc.

Corporate Governance

Cannabis Science, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.